A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

NCT04707313 on ClinicalTrials.gov · last registry update 2024-11-05

An unusually large phase 2: 628 participants, more than double the 110 typical for the stage. The sponsor logged completion for 13 September 2023. Primary outcome, as filed: Cohorts 1 and 2: Percent Change From Baseline in Body Weight at End of Treatment at Week 26. danuglipron is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.

Status: COMPLETED
Phase: P2
Drug: danuglipron
Sponsor: Pfizer
Sponsor type: Industry
Enrollment: 628
Started: 2021-01-29
Primary completion: 2023-09-13 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Cohorts 1 and 2: Percent Change From Baseline in Body Weight at End of Treatment at Week 26

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the danuglipron page for this molecule’s full trial and approval history.